Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (11619)	9/3/1999 12:42:00 PM
From: Steven Finkel	Read Replies (2) \| Respond to of 57584

Just added some sieb and abwg on anticipation of brokers rally at some point. It seems that no one is looking at them recently. Is this what you mean by timing the market? Meaning we buy what we know will do well while it is beaten down and no one cares...yet.

To: Rande Is who wrote (11619)	9/3/1999 12:48:00 PM
From: Hally	Respond to of 57584

Rande, IATR just went over the 2$ mark. Regards, Hally

To: Rande Is who wrote (11619)	9/3/1999 2:03:00 PM
From: Bucky Katt	Read Replies (3) \| Respond to of 57584

Yeah, HMGN They can't get enough of it. I think the TRGA news from yesterday was bigger, but heck, what do I know. I have sold HMGN for now, adding more TRGA. OLD news, check the new stuff,>SAN DIEGO, March 9 /PRNewswire/ -- NaviCyte, Inc., a wholly-owned subsidiary of Trega Biosciences, Inc. (Nasdaq: TRGA), announced today that it has entered into an agreement with Schering-Plough Corporation to collaborate on the use and development of NaviCyte's proprietary Pk-informatics tools to identify new candidates for drug development. Schering-Plough joins SmithKline Beecham, Genentech, and Parke-Davis as the fourth member of NaviCyte's IDEA(TM) Consortium to predict ADME characteristics of drugs, in silico. Not buying PBYP when my t/a said to buy, at 1.50, is my mistake of the year.